Holy Smokes GMPM up 50% Volume through the Roof!
researchdriveninvestor Newsletter
Research Driven Investor Why RDI ~~~~~~~~~~~~~~~~~~~~~~~~~~
RDI, – Research Driven Investor, reveals penny stocks with: proven management teams, increasing market share, ballooning revenues,low debt loads, improving financial ratios and much more…
Well-run companies that have great upside potential. Often these undiscovered, undervalued, or overlooked shares can multiply dramatically in value, over short time periods.
~~~~~~~~~~~~~~~~~~~~~~~~~~
Holy Sh@#! Do you see GMPM Up 50% as of 9:49AM (Est) Volume just blasted through 1,000,000 shares and it looks like there is no stopping this rocketship Hold on to your seats!! Breaking News Just Hit Wire on GMPM You better read fast! This could be the start of major move!! April 11, 2012, 7:10 a.m. EDT Gamma Pharmaceuticals, Inc. Launches Male Enhancement Product, Accepts Purchase Order with Deposit, Opens Exports Sales to Mexico ST. PAUL, Minn., April 11, 2012 /PRNewswire via COMTEX/ — Gamma Pharmaceuticals, Inc. (pinksheets:GMPM) reached a milestone in its strategic plan for the current fiscal year: The Company has accepted its first order for a Male Enhancement product for export to Mexico. Gamma`s customer is a large commercial operation in Mexico with distribution coverage and access to more than 15,000 retail locations.. The contract governing this relationship has a two-year term with automatic extensions, creating a long term opportunity for Gamma in this important market. A full range of Gamma`s products are under discussion and commercial review is underway.
Joseph Cunningham Gamma`s President commented, “Our customer is established and well positioned to provide full national retail coverage. The Mexican market is large and a gateway for other national territories in Latin America.” Separately, Gamma is announcing it has developed a proprietary, fast acting Male Enhancement oral GEL and is in the late stages of product testing. Gamma is leveraging the Company`s proprietary Gel Delivery Technology(TM) to solve a common complaint regarding the array of current products in the Erectile Dysfunction and Male Performance market: slow response time. Typically a pill or tablet can take up to 45 minutes to be effective. Gamma`s GEL Delivery Technology(TM) enables active ingredients to be absorbed up to 80 times faster than a pill or capsule, significantly compressing the time from ingestion to erection and providing Gamma with a clear competitive advantage. Over the past five years, sales for Male Enhancement products have steadily increased, exceeding $4.0 billion in 2011. Gamma views its fast acting entrant in this rapidly growing market as having the potential to gain meaningful market share.
Joseph Cunningham, Gamma`s President commented, “Gamma`s focus on alternative delivery systems for everyday health and wellbeing make the Male Enhancement market a natural opportunity for our proprietary knowledge and expertise. We are very excited to begin our export program to Mexico and beyond. We anticipate strong growth in this category and expansion of the product mix in the months ahead.” About Gamma Pharmaceuticals, Inc.
Gamma Pharmaceuticals, Inc. ( www.gammapharma.com ) is a marketing and product formulation company focused on alternative delivery systems for everyday health and wellness.
Gamma sells its own branded products through wholesalers and direct to retailers, both in the US and internationally. Gamma`s core focus is the marketing and sale of vitamins and nutraceuticals, OTC pharmaceutical products and personal care products in the United States. Branded nutritional supplements are sold under the trademarks Brilliant Choice(TM) nutritional supplements featuring the call to action, “You`ve made a brilliant choice for your nutrition;” SAVVY(TM) adult nutritional supplements featuring the call to action, “Be SAVVY Stay Healthy;” and, Gamma Energy Products(TM) a high performance supplement featuring the call to action, “Get Your Gamma On.” Gamma`s customer focus is on selling products in the Lifestyle of Health & Sustainability (“LOHAS“) marketplace and in the Energy Supplement Market. A series of innovative marketing programs support Gamma`s product sales and retail partners.
At present Gamma manufactures in North America and distributes in the United States and Mexico. Gamma`s products utilize proprietary “Gel Delivery Technology®”, to create innovative gel product forms that give consumers a more pleasant experience.
Gel Delivery Technology® characteristics include rapid absorption, superior texture, convenience and great taste. Market categories Gamma targets are growing as rapidly as 60% per year. Gamma has developed formulas and strategies for Metabolic Syndrome and Diabetes Type II, Stress Reduction, Cognition, Well-being, Menopause Symptoms and Personal Care Products. Gamma also develops and manufactures house brands for major retailers. At this time, Gamma has a total of 36 SKUs and holds licenses for 9 SKUs in China.
~~~~~~~~~~~~~~~~~~~~~~~~~~
Sincerely, Research Driven Investor www.ResearchDrivenInvestor.com As always do your own research on all profiles that I give. Penny stocks are risky, like most speculative investments. Always view the company websites and base your own opinion.
~~~~~~~~~~~~~~~~~~~~~~~~~~
Disclaimer and Safe Harbor Statement www.ResearchDrivenInvestor.com and its owners, and their affiliates, directors and officers, and immediate family members, are hereafter collectively referred to as “RDI” or “we” or “us” or “our”). RDI publishes information (the “Information”) about publicly traded companies (the “Profiled Company” or the “Profiled Companies”) which has been obtained from various sources including publicly available sources on the internet. RDI does not undertake any due diligence or investigation of the Information it obtains or publishes. You should not consider the Information published by RDI to be a true, accurate, complete or reliable. The Profiled Companies actual results and financial condition may differ materially and be completely different than that published or described in the Information. The Information is not an offer or solicitation to buy or sell securities of the Profiled Companies. You should not consider the Information to be a recommendation or indication as to when you should buy or sell securities or if you should buy or sell securities of the Profiled Companies. RDI and its officers, directors, owners and employees are not licensed as brokers, broker dealers, market makers, investment bankers, investment advisors, analysts or underwriters.
You should not consider the Information when making an investment decision of whether to buy or sell securities of any Profiled Company on RDI and you should consult with and request that your investment advisor or attorney verify any information you rely upon in making an investment decision. You should consult your financial and legal advisers before purchasing or selling the securities of any Profiled Company.
Affiliates, officers, directors and employees of RDI may own or may purchase shares of the Profiled Companies and may sell their securities at times when RDI publishes Information on the Profiled Company including when investors purchase the securities of the Profiled Companies.
RDI will not advise you prior to buying or selling the securities of the Profiled Companies does not and the Information should not be considered when making a decision to buy or sell securities of the Profiled Companies. The Information is not a solicitation or recommendation to buy, sell or hold securities and does not provide reliable information or analysis of the financial position of the Profiled Companies.. All statements in the Information are subject to change without notice and are not reliable. RDI is not liable for any investment decisions by its readers. Readers should independently investigate and fully understand all risks before investing in any Profiled Company.
The owners, associates, officers, directors and/or employees and/or principals of RDI may have stock positions in the Profiled Companies obtained from purchases in the open market or in private transactions. RDI will liquidate any securities of the Profiled Companies at its discretion without notification to any party including you even it has made published positive Information about a Profiled Company. By reviewing RDI`s website you accept these terms and conditions.
Any investment in the Profiled Companies involves a high degree of risk and involves risks and uncertainties, which may result in investors losing all of their invested capital. Past performance does not guarantee future results.
The information contained herein contains “forward-looking statements,” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are based upon expectations, estimates and projections at the time the statements are made and involve risks and uncertainties that could cause actual events to differ materially from those anticipated. Forward-looking statements may be identified thorough the use of words such as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should, or might occur. Any statements that express or involve predictions, expectations, beliefs, plans, projections, objectives, goals or future events or performance may be forward-looking statements. Factors that could cause actual results to differ materially include but are not limited to adverse economic conditions, intense competition, lack of meaningful research results, inadequate capital, termination of contracts or agreements, adverse publicity and news coverage, inability to carry out research, development and commercialization plans, loss or retirement of key executives and other key personnel, and other risks detailed in public information including but not limited to reports filed with the Securities and Exchange Commission and/or OTC Markets. obtained information about some of the Profiled Companies from the OTC Markets Website at www.otcmarkets.com or from the website of the Securities and Exchange Commission, at http://www.sec.gov without charge.
Buying and Selling of Shares:
RDI may sell any shares of the Profiled Companies for less than target prices set forth in the Information and may profit by selling their securities while investors are purchasing during the same time RDI publishes the Information.
The securities of the Profiled Companies are high risk, unstable, unpredictable and illiquid. The securities of the Profiled Companies are considered in most circumstances to be penny stocks and should not be purchased by anyone who cannot sustain a complete loss of their investment. If you cannot sustain the loss of your entire investment you should not purchase securities of the Profiled Companies. If at anytime you wish to be removed from our list simply
Related posts:
- GMPM is my “Big, Potential Winner” Read Who is in Charge!
- you read my email at 4PM? about….
- Huge News just Hit (GMPM) Watch this..
- GMPM Leading the Charge up 52 Percent, Boo Yaa!
- GMPM – Breaking News Just Hit The Wire!